Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. - Wikidata - awgldk - TriplyDB

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

http://www.wikidata.org/entity/Q35134071

about

Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS Current perspectives on HIV-1 antiretroviral drug resistance Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems Structure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating Phenyloxazolidinones Pyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than Ritonavir Interaction of human cytochrome P4503A4 with ritonavir analogs Substrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug Resistance HIV protease inhibitors: a review of molecular selectivity and toxicity BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism Using drug exposure for predicting drug resistance - A data-driven genotypic interpretation tool Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies.Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers Dolutegravir: clinical efficacy and role in HIV therapy.Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.Recent Structural Insights into Cytochrome P450 Function.Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease.CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.Molecular Basis for Drug Resistance in HIV-1 Protease P glycoprotein in human immunodeficiency virus type 1 infection and therapy.Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.HIV-1 antiretroviral drug therapy.Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism

P2860

Q24538763-6A56A957-CF68-4126-BE3A-66D34C79EB2F Q24554340-96EE9DF8-EE12-4A97-B2DD-9C6CAE1E7C7E Q26777251-A176AA21-8D29-4D1F-A35C-24B2243D45CB Q26852626-9BEA9288-009E-46BB-9222-4AB1F6BCC2DC Q26861370-6A4F0B83-AA1F-4EE7-ABAA-08A620FC283D Q27665164-B39B2AEB-ED71-420C-9669-A533151A3E49 Q27677369-759F0DF6-5E83-404B-8AB1-0E5E27F624F2 Q27678008-CFE88D36-0D3D-4F1A-92DD-7D2EB3CD3290 Q27679880-67ABCF7C-FA48-4B58-AEC8-69DFB4F93C25 Q28082749-0F3E7FC7-14E5-4F13-BA46-1D41B1889A5B Q28344472-5E943E03-F04F-4B01-BD6C-1417211D0538 Q28354163-013F8279-2A16-4123-A0A4-582EE35EA8FC Q28369297-D5F26159-4A77-4249-B2B3-60D7D8E81718 Q28379223-74481A57-904E-41A1-BDE3-DEEA655DFA5B Q28469113-BDD5396C-F523-4B22-84DC-A774923839FF Q30000270-E7774A3D-334B-4B6C-8FF8-DC628E8CFCEF Q33435327-00238C50-C3A3-41BA-B82F-735A90D06781 Q33651025-E55E96BA-296F-4AC7-A2F9-BD2BF7CFF161 Q33700538-76873D20-0130-416B-A3F6-6091F5260B47 Q33725024-B8F09D9D-83CF-4DBE-8D97-ED862B4B332E Q33795052-BE0B4FC2-3408-403B-B5A9-5C8D513A87F0 Q33861897-CC4D64A9-9194-4BB0-9E6B-A14A3869D49C Q33980711-B21EA3A1-B64C-4276-8864-FC6B0FBD2F30 Q33983571-8E8D543F-71EE-4312-9F30-E361DBC7646E Q34010283-85E4E0D3-23B3-41CF-9AB8-5B8B69DA7F96 Q34253139-BCC5D174-ECAC-440B-BA9F-E442437594E8 Q34529849-A692802E-14C6-4F83-AC7C-DF30F365D140 Q34674166-A4045B1A-949B-487E-85F0-95742578262D Q34719821-7380B62C-3EF3-45FF-8F9A-E4497BD9E439 Q34720072-E05584AC-882C-4E6D-AB4F-F5FE942F4C2A Q34778531-32DCF032-6EEA-4917-8343-B62670D030A9 Q34821530-016A9210-B8D1-4460-B9DA-3BA6B8D3EF53 Q35057007-DA89125B-822C-492B-9678-B3D53CC0F89E Q35057831-9DA02FB3-3987-4E5F-9647-5996469C2AE6 Q35260370-5E56BBF5-1391-4FEC-8CD3-65DDE1C36F2A Q35718765-ECC79BC3-D4E2-4DB6-83DF-261867E667AE Q35826686-E7928A08-DFA9-4507-85FB-E8A5B5A407C0 Q35827661-BB3AD932-D0BD-43F4-AC75-101B0BC24A2A Q35853012-5742373E-3CCD-4950-80E9-FE1A7D23F5CE Q35933538-4AA38B72-ECB6-4AB5-86BF-A7E3E90BFE50

P2860

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

http://www.wikidata.org/entity/Q35134071

description

1997 nî lūn-bûn

@nan

1997 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի մարտին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Pharmacokinetic enhancement of ...... administration with ritonavir.

@ast

Pharmacokinetic enhancement of ...... administration with ritonavir.

@en

type

label

Pharmacokinetic enhancement of ...... administration with ritonavir.

@ast

Pharmacokinetic enhancement of ...... administration with ritonavir.

@en

prefLabel

Pharmacokinetic enhancement of ...... administration with ritonavir.

@ast

Pharmacokinetic enhancement of ...... administration with ritonavir.

@en

P1433

Q35134071-9ADC6870-037D-4CD0-947D-5B41534DDB84

P1476

Q35134071-189D3765-CAE8-4B0B-A269-DCE3E1F26DD1

P2093

Q35134071-0C343BCB-5584-4331-82AA-A8429E9280C1

Q35134071-0FC6A5F3-A46F-47EE-B7AE-8E928AFF89F6

Q35134071-2448C18F-D52B-491A-91AA-37D2C5999C7E

Q35134071-2B0ADDD7-3C02-473B-B234-7FADD4D55067

Q35134071-5667A4C7-B8C7-4493-B9B8-3B25A6727519

Q35134071-70D3452E-76B9-4F50-8CF7-80622C78EC74

Q35134071-7B9771CC-B762-4DF3-9E0A-6435CCBFFCB2

Q35134071-888A019A-C97D-49CE-B979-0B753BD265F0

Q35134071-9003B3E1-E8A1-4A3F-B077-6963B9B85149

Q35134071-A300E0FC-4108-43DB-8994-D3011E322BCE

P2860

Q35134071-1B8A9C44-5A7F-450B-8258-F79095B321BF

Q35134071-30F4D919-D76A-41BA-849A-AFFE88B6672D

Q35134071-3120B8C8-13A0-42CA-934C-581812AE740A

Q35134071-32E2F839-D31E-4E34-9218-42AAAB56D8C0

Q35134071-417307AF-1918-489B-B84E-4E3587CA4E54

Q35134071-4AF6FC0B-7592-4DAB-BDDB-5D01DDA7A09E

Q35134071-53F4E8C6-B641-47C8-985B-014A8C03BB83

Q35134071-568685E6-D0A4-4340-954D-949835F489F6

Q35134071-65C4F6FD-1639-448B-B5EF-BAFF33777751

Q35134071-7379F2A7-61CF-4671-913F-61B4EBCC135B

P304

Q35134071-1246C5B5-F6A1-4BB4-99C8-23974F5073E0

P31

Q35134071-1B9578FD-D7A1-47C4-ADE7-FFA1DF3C9DA7

P356

Q35134071-2911FDB4-DA34-4DE6-91A3-F0480B2323B1

P407

Q35134071-751BA57B-DB74-4D7A-9542-43086E727F45

P433

Q35134071-3C298B4D-6AC8-45FA-9B6A-0B00EF97257F

P478

Q35134071-27380045-6DBB-4E0D-BDBF-417380EBC138

P577

Q35134071-2EE5AE83-0681-42AF-A189-2EE5D3CDDAD9

P698

Q35134071-B05A2BB2-92CC-4158-8D47-2BD7D2F4E244

P932

Q35134071-5CE906BF-5F17-4C93-B995-4F97D9726181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetic enhancement of ...... oadministration with ritonavir

@en

P2093

Baroldi PA

http://www.w3.org/2001/XMLSchema#string

Denissen JF

http://www.w3.org/2001/XMLSchema#string

Granneman GR

http://www.w3.org/2001/XMLSchema#string

Hsu A

http://www.w3.org/2001/XMLSchema#string

Kempf DJ

http://www.w3.org/2001/XMLSchema#string

Kukulka MJ

http://www.w3.org/2001/XMLSchema#string

Kumar G

http://www.w3.org/2001/XMLSchema#string

Leonard JM

http://www.w3.org/2001/XMLSchema#string

Marsh KC

http://www.w3.org/2001/XMLSchema#string

McDonald E

http://www.w3.org/2001/XMLSchema#string

P2860

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

Rational design of peptide-based HIV proteinase inhibitors

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

Viral dynamics in human immunodeficiency virus type 1 infection

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

P304

654-660

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.41.3.654

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

1997-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9056009

http://www.w3.org/2001/XMLSchema#string

P932

163767

http://www.w3.org/2001/XMLSchema#string